Türkiye is taking an ambitious step by launching a new investment fund to position itself as a hub for biotechnology and life sciences innovation.
Maxis Venture Capital Portfolio Management, a subsidiary of Türkiye's biggest private bank Işbank, is partnering with internationally recognized health care investment firm BioScience Managers (BSM) to establish the Türkiye BioScience Investment Fund.
The strategic partnership aims to blend local insights with international experience by focusing on innovative technologies born in Türkiye, developed by Turks living abroad, or otherwise connected to Türkiye.
Its mission is to finance science and technologies that can transform health care services and enable these ventures to compete in global markets.
The fund, scheduled for a final closing in the first quarter of 2026, has set a target size of $100 million. With an initial closing threshold of $50 million, the fund anticipates providing seed or growth capital between $5 million and $10 million per company.
Portfolio strategy
The fund plans to invest in a total of 10 to 12 startups, typically acquiring a maximum stake of 20% per company. The investment criteria target ventures in the development and commercialization stages, as well as early-to-mid-growth companies with strong proof-of-concept evidence.
The fund's duration is set for 10 years, with two optional one-year extensions.
Key factors making Türkiye an attractive investment hub for this initiative include low development costs, a strategic geographic location, robust government incentives, and a vast, untapped potential for innovation.
Speaking at the launch, Sezgin Lüle, deputy general manager of Işbank, emphasized that the fund is a testament to global confidence in Tür
Continue Reading on Daily Sabah
This preview shows approximately 15% of the article. Read the full story on the publisher's website to support quality journalism.